Existing investors Third Rock Ventures, General Catalyst Partners, AccelMed, Lumira Ventures and two strategic investors provided funds. The Tewksbury, Massachusetts-based company plans to use the funds to complete its ongoing RESPONDER-HF trial.

RESPONDER-HF evaluates the shunt at more than 65 institutions on three continents. The company expects the trial to generate the final supportive clinical data required to garner FDA approval. It hopes to gain the regulatory nod for its shunt as a breakthrough treatment for heart failure. The shunt treats preserved and mildly reduced ejection fraction (HFpEF/HFmrEF).